Combogic

Ibuprofen BP &
Paracetamol BP

Composition
Combogic 375 Tablet: Each film coated tablet contains Ibuprofen BP 125 mg & Paracetamol BP 250 mg.
Combogic 700 Tablet: Each film coated tablet contains Ibuprofen BP 200 mg & Paracetamol BP 500 mg.

Pharmacology
The pharmacological actions of ibuprofen and paracetamol differ in their site and mode of action. These complementary modes of action are synergistic which results in greater antinociception and antipyresis than the single actives alone. Ibuprofen is an NSAID that exerts an analgesic effect through peripheral inhibition of the cyclooxygenase-2 (COX-2) isoenzyme with a subsequent reduction in sensitization of nociceptive nerve terminals. In humans, ibuprofen reduces inflammatory pain & swellings. Paracetamol's exact mechanism of action is still not completely defined; however, there is considerable evidence to support the hypothesis of a central antinociceptive effect. Various biochemical studies point to inhibition of central COX-2 activity. Paracetamol may also stimulate the activity of descending 5-HT (serotonin) pathways that inhibit nociceptive signal transmission in the spinal cord.

Indications
It is indicated for the temporary relief of mild to moderate pains due to:
• headache • toothache • backache • menstrual cramps • muscular aches • minor pain of arthritis

Dosage and Administration

Combogic 375 mg Tablet	*Adults & Children over 12 years: 2 tablets, 3 times daily*
Combogic 700 mg Tablet	*Adults over 18 years: 1 tablet, 3 times daily*

*Do not take more than six tablets in any 24-hour period.
Elderly: No special dosage medications are required

Use in Special Population
Pregnancy and Lactation
There is no experience of use of this product in humans during pregnancy.

Pregnancy: NSAIDs should not be used during the first two trimesters of pregnancy or labor unless the potential benefit to the patient outweighs the potential risk to the fetus.
Therefore, if possible, the use of this product should be avoided in the first six months of pregnancy and contraindicated in the last three months of pregnancy

Lactation: Ibuprofen and its metabolites can pass in very small amounts into the breast milk. No harmful effects to infants are known.
Paracetamol is excreted in breast milk but not in a clinically significant amount. Available published data do not contraindicate breastfeeding.

Therefore, it is not necessary to interrupt breastfeeding for short-term treatment with the recommended dose of this product.

Renal & Hepatic Impaired Patients
The administration of NSAIDs may cause a dose dependent reduction in prostaglandin formation and precipitate renal failure. Patients at greatest risk of this reaction are those with impaired renal function, cardiac impairment, liver dysfunction so dosage adjustment is required for those patients.

Contraindications
• In patients with a known hypersensitivity to ibuprofen, paracetamol or any other excipients in the product. • In concomitant use with other Paracetamol-containing products • In patients with active, or a history of recurrent peptic ulcer • In patients with a history of, or an existing gastrointestinal ulceration/perforation. • In Patients with defects in coagulation • In patients with severe hepatic failure, severe renal failure or severe heart failure • In concomitant use with other NSAID containing products • During the last trimester of pregnancy

Warnings and Precautions
• Do not exceed the recommended dose. • The hazards of paracetamol overdose are greater in patients with non-cirrhotic alcoholic liver disease. Immediate medical advice should be sought in the event of an overdose, even if the patient feels well, because of the risk of delayed, serious liver damage. • Undesirable effects of ibuprofen may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms and by patients taking the dose with food • Consult a doctor if the symptoms persist or worsen or if the product is required for more than 3 days.

Side effects
The common adverse reactions in patients treated with paracetamol and ibuprofen were nausea, vomiting, headache, dizziness, somnolence, facial swelling, constipation etc.

Drug Interactions
• It is contraindicated in combination with other paracetamol containing products – increased risk of serious adverse effects. • It is contraindicated in combination with Acetylsalicylic acid. • Other NSAIDs including cyclo-oxygenase-2 selective inhibitors as these may increase the risk of adverse effects. • It should be used with caution in combination with Cholestyramine, Metoclopramide, Warfarin & Flucloxacillin. • It should be used with caution in combination with anticoagulants, antihypertensives (ACE inhibitors, Angiotensin II antagonist, diuretics), antiplatelet agents & SSRIs.

Overdose
Paracetamol
Liver damage is possible in adults who have taken 10 g or more of paracetamol. Ingestion of 5 g or more of paracetamol may lead to liver damage if the patient has one or more of the risk factors below: a) Is on a long-term treatment with carbamazepine, phenobarbitone, phenytoin, primidone, rifampicin, St John's Wort or other drugs that induce liver enzymes. b) Regularly consumes alcohol in excess of recommended amounts. c) Is likely to be glutathione depleted e.g., eating disorders, cystic fibrosis, HIV infection, starvation, cachexia. Immediate treatment is essential in the management of paracetamol overdose. Management should be in accordance with established treatment guidelines

Ibuprofen
In children ingestion of more than 400 mg/kg of Ibuprofen may cause symptoms. In adults the dose response effect is less clear cut. Management should be symptomatic and supportive and include the maintenance of a clear airway and monitoring of cardiac and vital signs until stable.

Storage
Do not store above 25^0 C. Protect from light. Keep out of reach of children.

Packaging
Combogic 375 Tablet: Each box contains 12x10's tablets in blister pack.
Combogic 700 Tablet: Each box contains 12x10's tablets in blister pack.

Manufactured by
ZISKA PHARMA **Ziska Pharmaceuticals Ltd.**
Kaliakoir, Gazipur, Bangladesh

P-3913

Version: 00